Stay updated on Phase II Pembrolizumab Plus GVD Clinical Trial
Sign up to get notified when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.

Latest updates to the Phase II Pembrolizumab Plus GVD Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to reflect a new phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed or refractory Hodgkin lymphoma, with changes in the study's description and collaborators.SummaryDifference23%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to December 18, 2024.SummaryDifference0.5%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to Phase II Pembrolizumab Plus GVD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.